Literature DB >> 16942118

US FDA guidance: apropos of PROs.

Paul Kind.   

Abstract

Mesh：

Year:  2006        PMID： 16942118     DOI： 10.2165/00019053-200624090-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  1 in total

1.  Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.

Authors:  Catherine Acquadro; Rick Berzon; Dominique Dubois; Nancy Kline Leidy; Patrick Marquis; Dennis Revicki; Margaret Rothman
Journal:  Value Health       Date:  2003 Sep-Oct       Impact factor: 5.725
  1 in total
  1 in total

1.  The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.

Authors:  Paul A Scuffham; Jennifer A Whitty; Andrew Mitchell; Rosalie Viney
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.